H o n o r a r y M e m b e r s h i p Prof. David Kerr.

Slides:



Advertisements
Similar presentations
Biomedical Ethics at the Wellcome Trust Jacob Leveridge Biomedical Ethics Programme.
Advertisements

Contemporary Islamic Studies at University of Aberdeen? Dr Gabriele Marranci Religious Studies.
Cancer Research UK strategy and funding Simon Vincent.
MRC Funded Research Opportunities
The Newton Fund Research and Innovation for Growth and Prosperity.
0 This document is CONFIDENTIAL and its distribution and use are RESTRICTED © 2012 KPMG LLP, a UK limited liability partnership and a member firm of the.
The South East Asia Rainforest Research Partnership (SEARRP)
Research strategy for RNOH-IOMS David Marsh Professor of Clinical Orthopaedics Institute of Orthopaedics and Musculoskeletal Science, University College.
MSc Facility and Environment Management UCL Introduction.
The Newton Fund Research and Innovation for Growth and Prosperity.
Welcome to the NIHR Peter Knight, Deputy Director Research Contracting, Information Intelligence and Stakeholder Engagement NIHR Trainees Meeting Leeds.
Institute for Health and Society Institute for Health and Society Improving Health and Advancing Health Equity Through Community and Academic Partnerships.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Clinical Academic Trainees’ Conference 3 November 2012 Clinical Lecturers and Post-doctorates Dolores Conroy PhD Director of Research Fight for Sight.
A Career in Oncology Dr H.K.Lord Consultant Clinical Oncologist.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
THE STERLING GROUP “Engineering excellence in UK universities”
CTOS: A Herman Suit Legacy Michael A. Simon, MD The University of Chicago.
Hale & Tempest India Biotech Briefing Dr. Brian W Tempest IBIZ Conference, NHS Expo Excel London UK 9 March 2011.
Clinical Pharmacology Jim Wright Clinical Pharmacologist 7 lectures.
David Strangway, PhD, FRSC, OC FORMER PRESIDENT University of Toronto, University of Toronto, University of British Columbia, Canada University of British.
The Newton Fund “Research and Innovation for Growth and Prosperity”
Sir David King Chief Scientific Adviser to UK Government UK and South Africa: Working in Partnership Cape Town 18 May 2005.
Academia Ophthalmologica Internationalis Oration 2008 Professor the Honourable Arthur K C Li.
AN INTRODUCTION TO EDEN AND TO THE CONFERENCE Professor Alan Tait, President of EDEN.
“GLOBAL MEDICAL RESEARCH: A WORK IN PROGRESS” Stuart E. Siegel, MD Director, Center for International Health Children’s Hospital Los Angeles Professor.
UNIVERSITY OF NAIROBI World Class University Committed to Scholarly Excellence Prof. Peter M.F. Mbithi, EBS Vice Chancellor.
Mission 2017 Panel Members. Professor Maarten de Wit Nelson Mandela Metropolitan University Founding and Science Director, Africa Earth Observatory Network.
Industry Symposium World Congress Tissue Engineering and Regenerative Medicine International Society Vienna, Austria September 5-8, 2012 Organized by TERMIS-AM.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
The School’s Research Environment Anne Mills Deputy Director and Provost Improving health worldwide
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
OMICS international Contact us at: OMICS International through its Open Access Initiative is committed to make genuine and.
OMICS international Contact us at: OMICS International through its Open Access Initiative is committed to make genuine and.
Higher Education Policies: Challenges and Opportunities Prof. David Taylor Pro Vice-Chancellor (International)
Foundation Doctors’ Academic Meeting Kathryn Adcock Wellcome Trust March 2011.
Khaldoon AlKhaldi, MD Disaster medicine / Pre-Hospital care & International EMS Fellow BIDMC Harvard Medical schoo l Evolution of research production of.
“Stronger Together We are”
Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest Pharmaceuticals.
Choosing Your Letter Writers: Making networking work for you
GRANTHAM-KNUST FAMILY MEDICINE TWINNING PROJECT
ROSEMARY BRYANT AO RESEARCH CENTRE
01 European Science Café Houston, Texas December Free event RSVP here
Reflections on my career and why it has developed as it has
Malcolm Lowe-Lauri Executive Director at CUHP
Health Challenges & Opportunities
Annual Business Meeting & Class of 2017 Fellows
Get Your Treatment Done from the Top Dermatologists in Delhi NCR
Managing symptomatic asthma in primary care: The personalised approach
Action: BM0806 Recent Advances in Histamine Receptor H4R Research
School of Business, Economics and Law at the University of Gothenburg
Challenges of Cancer in Vermont and Rural Northern New England
Amir Hussain’s Brief Biography
The Art of Capturing Pluripotency: Creating the Right Culture
UCD School of Medicine & Medical Science
Meeting with the Ethiopian Delegation on the 13th May 2016
Honorary member 2018 Prof. Valerie J. Lund.
Salahadin Abdi, MD, PhD Professor and Chairman
What is ENGOT? Antonio González Martín
OUR INVOLVEMENT STRATEGY 2018/19
H o n o r a r y M e m b e r s h i p Prof. Dr. Karim Fizazi.
CanMEDS Roles Covered X
Intermediate Fellowships
UKCRC Public Health Research Centres of Excellence
BDHP Cancer Theme Seminar Haematology Cancers
Transforming healthcare with 5G – HIMSS & HEALTH 2
Top 200 Universities in the World Queen’s is in the Top 200 Universities in the World (QS World University Rankings 2019)
STRATEGIC PLAN.
Is STEM for me ? What’s a STEM career ? STEM in career STEM employment
Director HIPEC programme
Presentation transcript:

H o n o r a r y M e m b e r s h i p Prof. David Kerr

Medical and science degrees H o n o r a r y M e m b e r s h i p Medical and science degrees   1980 - MBChB University of Glasgow 1987 - MD 1990 - MSc In Clinical Pharmacology PhD Regulation of proliferation of breast cancer cells by growth factors 1996 - DSc The molecular and clinical pharmacology of anticancer therapy 2002 - MA University of Oxford

Medical Oncology Carreer H o n o r a r y M e m b e r s h i p Medical Oncology Carreer   1984 - 1992 University of Glasgow 1990 - present Honorary Professor of Pharmacology, University of Strathclyde 1992 - 2001 University of Birmingham 2001 - present University of Oxford 2009 - 2010 Sidra Medical and Research Centre, Doha, Qatar (leave of absence) 2009 - 2011 President, European Society of Medical Oncology 2010 - Professor of Cancer Medicine, Oxford University Hospitals Trust 2010 - 2012 Seconded as Health Adviser to Sec State for Health ,UK 2015 - Honorary Professor, 2nd Military University of Shanghai Honorary Professor, University of Xiamen Editor in Chief, Journal of Global Oncology

Honours and Fellowships H o n o r a r y M e m b e r s h i p Honours and Fellowships   1995 Elected Fellow of Royal College of Physicians and Surgeons, Glasgow (FRCP, Glas) 1996 Elected Fellow of Royal College of Physicians, London (FRCP, Lon) 2000 Elected Fellow of Academy of Medical Sciences (FMed Sci) 2002 Awarded Commander of Order of British Empire, by HM the Queen (CBE) 2007 Elected Honorary Fellow of Royal College of General Practitioners (FRCGP) 2009 Elected Founding Fellow of European Academy of Cancer Sciences (FCanSci) 2010 Elected Fellow of Royal College of Physicians, Edinburgh (FRCP, Edin) 2011 Adjunct Professor of Medicine, Weill-Cornell College of Medicine (NY) 2016 Honorary Prof of Oncology, 2nd Military University of Shanghai Honorary Prof of Oncology, Xiamen University

International collaborations H o n o r a r y M e m b e r s h i p International collaborations   USA He is in NIH’s Translational Research working group as the overseas member and have established a series of collaborations with the USA’s major cancer research centres (Mayo Clinic, MD Anderson, Memorial Sloan Kettering and Dana Farber, Harvard). INDIA He constructed a network of India’s top 10 cancer centres, in partnership with Oxford. This collaboration will provide training opportunities for Indian investigators in Oxford and will build an internationally competitive clinical research network (www.indox.org.uk). EUROPE He co-chaired the Entente Cordiale Celebrations on behalf of HM the Queen and President Chirac, 2003-2005. As President of ESMO (2010-2012) He was in a strong position to improve standing of Medical Oncology in Europe and sit on the Dutch government’s central committee for translational research. AFRICA He has established a consortium to develop cancer control programmes in Sub Saharan Africa and created AfrOx (www.afrox.org) the vehicle to implement change. FAR EAST He has established OxOnics, a drug development. It has a mission to bring novel anti-cancer agents to the Asia-pacific rim with a focus on China.

H o n o r a r y M e m b e r s h i p György you asked me about what comes first to my mind when thinking of David Kerr “David Kerr is one of the most influential, innovative and successful experimental and clinical researcher in the european oncology over the past 20-30 years. By his work and his functions in the European societies, in particular as EIC of “AnnOncology” and  ESMO-president, he contributed substantially to the development of medical oncology in Europe; beyond this, his impact on the development of health system and oncology treatment of  the poor countries in the world is really strong and valuable. David is not only a very good friend, but also an important and highly valuable partner of the board of Honorary Members of the Hungarian Society of Clinical Oncology.” Hans Joachim Schmoll

H o n o r a r y M e m b e r s h i p György you asked me about what comes first to my mind when thinking of David Kerr “I know David already for many years, but we met only a few times over those years. I know from the time he was editor-in-Chief of Annals of Oncology, when he was member of the ESMO Board and was President of ESMO. Moreover, we worked together on the Oxford Textbook of Oncology, one of the most important multidisciplinary textbooks in oncology today, of which he was the co-editor. He is a strong networker, with leadership capacity, is a kind person to talk with and excellent person to drink a beer with. I wholeheartedly welcome him into our illustrious family.” Jan Vermorken

H o n o r a r y M e m b e r s h i p György you asked me about what comes first to my mind when thinking of David Kerr “Very well deserved election to Honorary Member of the Society: David is an excellent example of merging between strong personal contribution to highly sophisticated translational research and a planetary vision of the problems of oncology from both  scientific , clinical and social prospectives.” Alberto Sobrero

H o n o r a r y M e m b e r s h i p György you asked me about what comes first to my mind when thinking of David Kerr “David is a highly Qualified Academic  Skilled And Respectable. He is obviously the first global world oncologist: Oxford, Scotland, England, UK being too small for him. He has already reconquered the Commonwealth: middle East, India, Africa… His goal is now the universe with its galaxies, black holes and quasars!  ……………. Aimery de Gramont

Welcome to the top Society. Aimery H o n o r a r y M e m b e r s h i p Between us, it is for life since we visited Lenin in 2004 after an overdose of Vodka. Welcome to the top Society. Aimery

H o n o r a r y M e m b e r s h i p If someone asks why Professor David Kerr was selected to become a Honorary Member of the Hungarian Society of Clinical Oncology? The answer is easy:

He is a strong networker, with leadership capacity H o n o r a r y M e m b e r s h i p He is one of the most influential, innovative and successful experimental and clinical researcher in the european oncology   He is a strong networker, with leadership capacity   He has a planetary vision of the problems of oncology     He has already reconquered the Commonwealth: middle East, India, Africa… His goal is now the universe with its galaxie………… Excellent person to drink a beer or an overdose of Vodka with